Fig. 6
From: Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer
ONC201 inhibited tumor growth in the LKB1fl/fl/p53fl/fl mouse model of EC. The LKB1fl/fl p53fl/fl mouse genetically engineered mouse model of EC was used to evaluate the effect of ONC201 in vivo. The obese (HFD) or lean (LFD) mice were injected Ad Cre into left side of uterus at 6–8 weeks of age to induce ECs. After 8 weeks of injections, the mice were treated with ONC201 (130 mg/kg, oral, weekly) or vehicle for 4 weeks. The mean tumor weight was reduced in the ONC201 treatment groups in both obese and lean mice (a). Serum VEGF from each group was measured by ELISA assay (b). ONC201 decreased serum VEGF level in obese and lean mice treated with ONC201. The expression of KI67, VEGF, phosphorylated-S6 and BCL-2 was assessed using immunohistochemistry following ONC201 or placebo treatment in endometrial tumors under obese and lean conditions (c). ONC201 significantly reduced the expression of Ki67, VEGF, BCL-2 and phosphorylated-S6 in endometrial tumors under obese and lean conditions. *p < 0.05 and **p < 0.01